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phenylpyrazole-4-carboxaldehyde (1) using appropriate synthetic routes. Newly synthesized com-
pounds were characterized using elemental analysis, spectral data (IR, 1H NMR, 13C NMR and
mass spectrometry) and were evaluated for their in vitro antimicrobial activity. The minimum inhib-
itory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal
concentration (MFC) were determined for the test compounds as well as for reference standards.
The investigation of antimicrobial screening revealed that compounds (3, 5) showed good antibac-
terial and antifungal activities, respectively.
ª 2011 King Saud University. Production and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.1. Introduction
In recent years, the number of life-threatening infectious dis-
eases caused by multi-drug resistant Gram-positive and
Gram-negative pathogen bacteria has reached an alarming le-
vel in many countries around the world (Berber et al., 2003;412653054.
.co.in (Z.N. Siddiqui).
y. Production and hosting by
Saud University.
lsevier
ND license.Mitscher et al., 1999). Morbidity and mortality because of en-
teric bacterial infection are the major health problems in some
areas like the Indian subcontinent, portions of South America
and tropical fraction of Africa (Qadri et al., 2005; Devasia
et al., 2006). Every year millions of people are being killed
by some or the other Gram-positive and Gram-negative strains
of bacteria. These bacteria mostly lead to food poisoning,
rheumatic, salmonellosis and diarrhea (Khan et al., 2008).
Thus, antibiotics provide the main basis for the therapy of
microbial (bacterial and fungal) infections. However, overuse
of antibiotics has become the major factor for the emergence
and dissemination of multi-drug resistant strains of several
groups of microorganisms (Harbottle et al., 2006). Further-
more, the pharmacological drugs available are either too
expensive or have undesirable side effects or contraindications
(Berger, 1985). Thus, in light of the evidence of rapid global
spread of resistant clinical isolates, the need to ﬁnd new anti-
microbial agents is of paramount importance.
238 Z.N. Siddiqui et al.Pyrazole derivatives, important heterocyclic analogs, are
promising candidates in this context as they possess wide spec-
trum of biological activities. They are extensively studied and
used as antimicrobial agents (Menozzi et al., 2004; Tandon
et al., 2005; Agarwal et al., 2006; Akbas and Berber, 2005).
Several pharmaceutical drugs including celecoxib (Penning
et al., 1997) and rimonabant (Deng and Mani, 2008) utilize
the pyrazole as their core molecular entity (Katritzky et al.,
2001; Deng and Mani, 2006). Many pyrazole derivatives are
reported to have the broad spectrum of biological activities,
such as anti-inﬂammatory (Bekhit et al., 2008), antifungal
(Prakash et al., 2008), herbicidal (Ohno et al., 2004), cytotoxic
(Vera-Divaio et al., 2009) and A3 adenosine receptor antago-
nists (Baraldi et al., 2003). In particular, 5-chloropyrazole
derivatives are reported to show potential antimicrobial (Ku-
mar et al., 2009), analgesic and anti-inﬂammatory activities
(Girisha et al., 2010). Numerous synthetic pyrazole derivatives
are also found used in various pharmaceuticals, agrochemicals,
photographic and other applications. Such examples of impor-
tant pyrazole derivatives are natural products (S)-pyrazolylala-
nine, pyrazomycin and synthetic compounds sildenafﬁl,
ionazolac, difenamizole, mepirizole etc. (Riyadh et al., 2010).
In search of more potent antibiotics, herein we report the
one pot, efﬁcient and simple methodology for the synthesis
of novel halopyrazole derivatives in good yields by using 5-
chloro-3-methyl-1-phenylpyrazole-4-carboxaldehyde as start-
ing material. The synthesized compounds were screened for
their in vitro antibacterial and antifungal activities.2. Experimental
2.1. General
Melting points were taken inReichert Thermover instrument and
are uncorrected. The IR spectra were recorded on Perkin Elmer
RXI spectrometer in KBr. 1H NMR spectra were recorded on
Bruker DRX-300 and Bruker Avance II-400 spectrometer using
tetramethyl silane (TMS)asan internal standard. 13CNMRspec-
trawere recordedonaBrukerDRX400Spectrometer (100 MHz)
with DMSO. Mass spectra were recorded on JEOL-Accu TOF
JMS-T100LC DART-MS spectrometer. Microanalytical data
were collected using Carlo Erba analyzer model 1108. The purity
of all compoundswas checked byTLCon glass plates (20 · 5 cm)
coated with silica gel (E-Merck G254, 0.5 mm thickness). The
plates were run in chloroform–methanol (4:1) mixture and were
visualized by iodine vapors. The compounds 1 (Pawar and Patil,
1994) and 2 (Jursic andNeumann, 2001) were synthesized from3-
methyl-1-phenylpyrazole-5-one, 1,3-dimethylbarbituric acid,
respectively by reported procedures.2.2. Synthesis of compound 3
To a well stirred solution of 5-acetyl-1,3-dimethylbarbituric
acid (4.52 mmol) in ethanol (12 ml) containing pyridine
(0.5 ml), 5-chloro-3-methyl-1-phenylpyrazole-4-carboxalde-
hyde (4.52 mmol) was added in the portion. The reaction mix-
ture was then stirred at room temperature for 1 h. Bromine
(4.52 mmol) was then added dropwise to the vigorously stirred
solution over a period of 20 min. After complete addition of
Br2 the reaction mixture was further stirred for another 3 h.The monobromoderivative 3 was precipitated, ﬁltered off,
and washed with 15 ml of ether to remove the excess of bro-
mine. Further puriﬁcation was made by recrystallization from
the chloroform–methanol (4:1v/v) mixture.
2.2.1. (Z)-2-Bromo-3-(5-chloro-3-methyl-1-phenylpyrazol-4-
yl)-1-(1,3-dimethyl-2,4,6-pyrimidinetrione-5-yl)prop-2-ene-1-
one (3)
Pale yellow crystals; m.p. 180–182 C, isolated yield 87%, IR
(KBr, cm1): 1730 (C‚O), 1689 (C‚O),1623 (C‚C); 1H
NMR (400 MHz, CDCl3): dH 2.61 (s, 3H, CH3), 3.32 (s, 3H,
N–CH3), 3.48 (s, 3H, N–CH3), 7.46–7.62 (m, 5H, Ar-H),
7.81 (s, 1H, Ha).
13C NMR (100 MHz, DMSO): dc 14.27,
27.73, 29.28, 38.94, 108.52, 124.53, 124.99, 128.40, 128.67,
128.79, 137.13, 148.57, 157.13, 165.12, 174.42. ESI–MS m/z:
480.6 (M+). Anal. Calcd. For C19H16N4O4BrCl: C, 47.57; H,
3.35; N, 11.67. Found: C, 47.42; H, 3.49; N, 11.56.
2.3. Synthesis of compound 5
A mixture of 5-chloro-3-methyl-1-phenylpyrazole-4-carboxal-
dehyde (4.52 mmol), 2,4-dinitrotoluene (4.52 mmol) and pyri-
dine (0.3 ml) in ethanol (12 ml) was reﬂuxed in a heating
mantle for about 2.5 h. On completion of reaction (as checked
by TLC), the reaction mixture was poured into 25 ml ice cold
water, acidiﬁed with conc-HCl. The solid, thus, obtained was
ﬁltered washed with water, methanol, dried and puriﬁed by
recrystallization from chloroform–methanol (3:2 v/v) mixture.
2.3.1. 5-Chloro-4-[2-(2,4-dinitrophenyl)-vinyl]-3-methyl-1-
phenyl-1H-pyrazole (5)
Yellow crystals; m.p. 122–125 C, isolated yield 84%, IR (KBr,
cm1): 1597 (C‚C), 1535 (C‚N), 1345 (C–N). 1H NMR
(300 MHz, CDCl3): dH 2.54 (s, 3H, CH3), 7.20 (d, 1H,
J= 16.5 Hz, Ha), 7.35–7.57 (m, 5H, Ar–H), 7.66 (d, 1H,
J= 16.5 Hz, Hb), 8.00 (d, 1H, J= 8.7 Hz, Hc), 8.45 (d, 1H,
J= 8.7 Hz, Hd), 8.85 (s, 1H, He).
13C NMR (100 MHz,
DMSO): dc 14.65, 115.11, 117.54, 120.84, 120.99, 124.98,
125.28, 128.72, 129.28, 129.39, 139.37, 147.12, 149.05, 151.85.
ESI–MS m/z: 384.12 (M+). Anal. Calcd. For C18H13N4O4Cl:
C, 56.19; H, 3.40; N, 14.56. Found: C, 56.06; H, 3.53; N, 14.51.
2.4. Antibacterial studies
The newly synthesized compounds were screened for their anti-
bacterial activity against Streptococcus pyogenes (clinical iso-
late), Methicillin resistant Staphylococcus aureus (MRSA
+ve), Pseudomonas aeruginosa (ATCC-27853), Klebsiella
pneumoniae (clinical isolate) and Escherichia coli (ATCC-
25922) bacterial strains by disk diffusion method (Cruickshank
et al., 1975; Collins, 1976). A standard inoculums (1–
2 · 107 c.f.u./ml 0.5 McFarland standards) was introduced
onto the surface of sterile agar plates and a sterile glass sprea-
der was used for even distribution of the inoculums. The disks
measuring 6 mm in diameter were prepared from Whatman
no. 1 ﬁlter paper and sterilized by dry heat at 140 C for 1 h.
The sterile disks previously soaked in a known concentration
of the test compounds were placed in nutrient agar medium.
Solvent and growth controls were kept. Ciproﬂoxacin (30 lg)
was used as positive control while the disk poured in DMSO
was used as negative control. The plates were inverted and
incubated for 24 h at 37 C. The susceptibility was assessed
Table 1 Antibacterial activity of compounds 3, 5 and positive control ciproﬂoxacin.
Compounds Diameter of zone of inhibition (mm)
Gram-positive bacteria Gram-negative bacteria
S. pyogenes MRSAa P. aeruginosa K. pneumoniae E. coli
3 19.4 ± 0.4 19.4 ± 0.4 26.3 ± 0.4 14.6 ± 0.2 18.7 ± 0.4
5 19.2 ± 0.2 18.2 ± 0.2 25.2 ± 0.2 14.1 ± 0.4 17.5 ± 0.2
Standard 22.5 ± 0.4 21.5 ± 0.4 31.0 ± 0.2 19.0 ± 0.2 27.0 ± 0.4
DMSO – – – – –
Positive control (Standard); ciproﬂoxacin and negative control (DMSO) measured by the Halo Zone Test (unit, mm).
a Methicillin resistant Staphylococcus aureus (MRSA +ve).
Table 2 MIC and MBC results of compounds 3, 5 and positive control ciproﬂoxacin.
Compounds Gram-positive bacteria Gram-negative bacteria
S. pyogenes MRSA P. aeruginosa K. pneumoniae E. coli
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
3 12.5 50 25 50 25 100 25 100 50 100
5 12.5 100 25 50 50 100 50 100 25 100
Standard 6.25 12.5 6.25 12.5 12.5 25 6.25 25 6.25 25
MIC (lg/ml), minimum inhibitory concentration, i.e., the lowest concentration of the compound to inhibit the growth of bacteria completely;
MBC (lg/ml), minimum bactericidal concentration, i.e., the lowest concentration of the compound for killing the bacteria completely.
Table 3 Antifungal activity of compounds 3 and 5. Positive
control (Griseofulvin) and negative control (DMSO) measured
by the Halo Zone Test (Unit, mm). Diameter of zone of
inhibition (mm).
Compounds CA AF TM PM
3 21.4 ± 0.2 19.9 ± 0.3 16.2 ± 0.2 13.5 ± 0.4
5 21.2 ± 0.4 18.4 ± 0.2 15.3 ± 0.4 12.2 ± 0.2
Standard 30.5 ± 0.2 26.5 ± 0.2 23.5 ± 0.3 21.5 ± 0.5
DMSO – – – –
CA: Candida albicans, AF: Aspergillus fumigatus, TM: Trichophy-
ton mentagrophytes, PM: Penicillium marneffei.
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positive and Gram-negative strains of bacteria. Inhibition
zones were measured and compared with the controls. The
bacterial zones of inhibition values are given in Table 1.
Minimum inhibitory concentrations (MICs) were deter-
mined by broth dilution technique. The nutrient broth, whichTable 4 MIC and MFC of compounds 3 and 5. Positive control gr
Comp CA AF
MIC MFC MIC M
3 25 50 25 1
5 50 100 50 1
Standard 6.25 25 12.5 2
CA: Candida albicans, AF: Aspergillus fumigatus, TM: Trichophyton m
inhibitory concentration, i.e., the lowest concentration of the compound
fungicidal concentration, i.e., the lowest concentration of the compoundcontained logarithmic serially two fold diluted amount of test
compound and controls was inoculated with approximately
5 · 105 c.f.u./ml of actively dividing bacteria cells. The cultures
were incubated for 24 h at 37 C and the growth was moni-
tored visually and spectrophotometrically. The lowest concen-
tration (highest dilution) required to arrest the growth of
bacteria was regarded as minimum inhibitory concentration
(MIC). To obtain the minimum bactericidal concentration
(MBC), 0.1 ml volume was taken from each tube and spread
on agar plates. The number of c.f.u. was counted after 18–
24 h of incubation at 35 C. MBC was deﬁned as the lowest
drug concentration at which 99.9% of the inoculums were
killed. The minimum inhibitory concentration and minimum
bactericidal concentration are given in Table 2.
2.5. Antifungal studies
Antifungal activity was also done by disk diffusion method.
For assaying antifungal activity Candida albicans, Aspergillus
fumigatus, Trichophyton mentagrophytes and Penicillium mar-
neffei were recultured in DMSO by agar diffusion methodiseofulvin.
TM PM
FC MIC MFC MIC MFC
00 12.5 50 50 100
00 25 100 50 100
5 6.25 25 12.5 25
entagrophytes, PM: Penicillium marneffei. MIC (lg/ml), minimum
to inhibit the growth of fungi completely; MFC (lg/ml), minimum
for killing the fungi completely.
Table 5 PBE and fungicidal/fungistatic activity (MFC/MIC) of compounds 3, 5.
Compounds PBE = 100/MIC MFC/MIC
Bacteria tested Fungi tested
SP MRSA PA KP EC CA AF TM PM
3 8 4 4 4 2 2 4 4 2
5 8 4 2 2 4 2 2 4 2
Ciproﬂoxacine 16 16 8 16 16 – – – –
Griseofulvin – – – – – 4 2 4 2
SP: S. pyogenes, MRSA: Methicillin resistant Staphylococcus aureus, PA: P. aeruginosa, KP: K. pneumoniae, EC: E. coli, CA: C albicans, AF: A.
fumigatus, TM: T. mentagrophytes, PM: P. marneffei.
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pared by dissolving peptone (1 g), D-glucose (4 g) and agar
(2 g) in distilled water (100 ml) and adjusting pH to 5.7. Nor-
mal saline was used to make a suspension of spore of fungalN
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transferred to 3 ml saline to get a suspension of corresponding
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of compounds 3 and 5.
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punch, wells were made and each well was labeled. A control
was also prepared in triplicate and maintained at 37 C for
3–4 days. The fungal activity of each compound was compared
with griseofulvin as standard drug. Inhibition zones were mea-
sured and compared with the controls. The fungal zones of
inhibition values are given in Table 3. The nutrient broth,
which contained logarithmic serially two fold diluted amount
of test compound and controls was inoculated with approxi-
mately 1.6 · 104–6 · 104 c.f.u./ml. The cultures were incubated
for 48 h at 35 C and the growth was monitored. The lowest
concentration (highest dilution) required to arrest the growth
of fungi was regarded as minimum inhibitory concentration
(MIC). To obtain the minimum fungicidal concentration
(MFC), 0.1 ml volume was taken from each tube and spread
on agar plates. The number of c.f.u. was counted after 48 h
of incubation at 35 C. MFC was deﬁned as the lowest drug
concentration at which 99.9% of the inoculums were killed.
The minimum inhibitory concentration and minimum fungi-
cidal concentration are given in Table 4.
The PBE (percentual bacteriostatic efﬁciency, %) was ob-
tained as, PBE = 100/MIC and fungicidal/fungistatic activityN
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Scheme 2 Reaction sequence fo(MFC/MIC) as obtained are presented in Table 5. The ratio
MFC/MIC was calculated in order to determine if the com-
pound had a fungistatic (MFC/MICP 4) or fungicidal
(MFC/MIC 6 4) activity and the results have been summa-
rized in Table 5.3. Results and discussion
3.1. Chemistry
Due to the exceptional reactivity of formyl group in 5-chloro-3-
methyl-1-phenylpyrazole-4-carboxaldehyde, 1 was taken as
synthon for the generation of novel bioactive molecular frame-
works. Initially attempts were made to synthesize monobromo
derivative 3 starting from 1 and 5-acetyl-1,3-dimethylbarbituric
acid 2 in ethanol under basic medium followed by the subse-
quent addition of bromine with vigorous stirring at room tem-
perature (Scheme 1). The reaction sequence has been outlined
in Scheme 2. The reaction of heteroaldehyde 1 with heteroaryl
active methyl compound 2 in ethanol under basic medium
might have generated a,b-unsaturated system A. DropwiseN
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r the formation of product 3.
242 Z.N. Siddiqui et al.addition of bromine into the reaction mixture probably resulted
in the formation of dibromodihydro derivative B, which on
subsequent dehydrohalogenation afforded the required mono-
bromo derivative of chalcone 3. In another reaction, efforts
were made to synthesize styryl pyrazole 5, by the reaction of
1 with 2,4-dinitrotoluene 4 in reﬂuxing ethanol with catalytic
amount of pyridine. The reaction as visualized afforded the
product 5 in quantitative yield in short span of time (2.5 h).
The same reaction was carried under ethanol-pyridine, Br2
reaction condition did not afford the expected monobromo
derivative, instead the reaction stopped at the styryl pyrazole
product stage, 5 probably because of the steric hindrance from
the bulky aromatic or heteroaromatic rings. This fact was fur-
ther proved by the incompleteness of the bromination reaction
of isolated styryl pyrazole 5 (Scheme 1). The structures of the
compounds isolated were characterized by elemental and spec-
tral analysis (IR, 1H NMR, 13C NMR andMass spectrometry).
The infrared (IR) spectrum of 3 showed the carbonyl
absorption band of barbituric moiety at 1730 cm1. The
absorption bands for carbonyl group and carbon–carbon dou-
ble bond of the a,b-unsaturated system appeared at 1689 and
1623 cm1, respectively. The 1H NMR spectrum showed Ha
proton as sharp upﬁeld singlet at d 7.81. The aromatic protons
of the N-phenyl-pyrazole-moiety were present in the form of
multiplet at d 7.46–7.62. Six protons of N–CH3 groups were
discernible as two sharp singlets at d 3.32 and 3.48 whereas
protons of CH3 group of pyrazole unit were present in the
form of another sharp singlet at d 2.61. The 13C NMR spec-
trum was in accordance with the structure. Further conﬁrma-
tion of the structure was done by mass spectrum, which
showed M+ at 480.6 as base peak. The 1H NMR spectrum
of 5 showed Ha and Hb protons as doublets at d 7.20
(J= 16.5 Hz), 7.66 (J= 16.5 Hz) respectively. The other
peaks were observed at their normal position and are given
in the experimental section.
3.2. Antimicrobial activity
The investigation of antibacterial screening data (Tables 1 and
2) revealed that all the tested compounds showed moderate to
good bacterial inhibition. All the compounds showed good
inhibition against S. pyogenes, Methicillin resistant Staphylo-
coccus aureus (MRSA +ve) P. aeruginosa, K. pneumoniae
and E. coli species. MIC of compounds was in the range of
12.5–50 lg/ml. The MBC of compounds was found to be
two or four folds higher than the corresponding MIC results.
The antifungal screening data (Tables 3 and 4) showed moder-
ate to good activity. The compounds, 3 and 5 showed good
fungicidal activity against C. albicans, A. fumigates, T. mentag-
rophytes and P. marneffei fungal strains. MIC of compounds
was in the range of 12.5–50 lg/ml. The MBC of the com-
pounds was found to be two or four folds higher than the cor-
responding MIC results. Most of the compounds showed good
fungicidal activity against various fungal strains (Table 5).4. Conclusion
In summary, a clean and convenient synthesis of novel halopy-
razole derivatives has been developed. The procedure offers
several advantages including mild reaction conditions as well
as simple experimental and product isolation procedures, thus,making the current protocol as a useful and interesting meth-
odology for the synthesis of series of novel heterocycles in
good yields from cheap and readily available starting materi-
als. The antibacterial, antifungal screening data revealed that
newly generated compounds are potential antimicrobial
agents. The importance of such kind of work lies in the possi-
bility that the new compounds might be more effective against
microbes for which a thorough study regarding the structure–
activity relationship, toxicity and their biological effects would
be helpful in designing more potent antimicrobial agents. The
other biological evaluations may furnish some other important
applications.Acknowledgments
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